Facebook Linkedin RSS Twitter Youtube
Home 2023

Triple-negative breast cancer

Protein Inhibitor Approach Gets Reassessed for Cancer Therapy
Cancer

Protein Inhibitor Approach Gets Reassessed for Cancer Therapy

Biological Markers Uncovered in Triple-Negative Breast Cancer
Cancer

Biological Markers Uncovered in Triple-Negative Breast Cancer

Triple-Negative Breast Cancer’s Molecular Changes Revealed
Cancer

Triple-Negative Breast Cancer’s Molecular Changes Revealed

Breast Cancer Becomes Vulnerable to Immune Cells Through DDR1 Deactivation
Cancer

Breast Cancer Becomes Vulnerable to Immune Cells Through DDR1 Deactivation

Resistance to Drug for Triple-Negative Breast Cancer Identified
Cancer

Resistance to Drug for Triple-Negative Breast Cancer Identified

New Therapy Targets Aggressive Chemotherapy-Resistant Breast Cancer
Cancer

New Therapy Targets Aggressive Chemotherapy-Resistant Breast Cancer

Targeting Macrophages May Improve PARP Inhibitor Therapy for Triple-Negative Breast Cancer
Cancer

Targeting Macrophages May Improve PARP Inhibitor Therapy for Triple-Negative Breast Cancer

Merck & Co. Commits Up to $4.2B toward Seattle Genetics Cancer Partnerships
Cancer

Merck & Co. Commits Up to $4.2B toward Seattle Genetics Cancer Partnerships

Gilead to Acquire Immunomedics for $21B, Adding Breast Cancer ADC to Oncology Portfolio
Cancer

Gilead to Acquire Immunomedics for $21B, Adding Breast Cancer ADC to Oncology Portfolio

New Potential Targeted Therapy in Triple-Negative Breast Cancer
Cancer

New Potential Targeted Therapy in Triple-Negative Breast Cancer

1234Page 2 of 4
Copyright © 2025 Genetic Engineering & Biotechnology News. All Rights Reserved.